system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Biopsy, Needle, Blotting, Western, Carcinoma, Squamous Cell, Cohort Studies, Disease-Free Survival, Esophageal Neoplasms, Female, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Neoplasm Invasiveness, Neoplasm Staging, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Protein Array Analysis, Protein Tyrosine Phosphatase, Non-Receptor Type 12, Protein Tyrosine Phosphatases, Retrospective Studies, Risk Assessment, Sensitivity and Specificity, Survival Rate, Treatment Outcome.
user
Is tyrosine-protein phosphatase nonreceptor type 12 a novel prognostic biomarker for esophageal squamous cell carcinoma? Context: Tyrosine-protein phosphatase nonreceptor type 12 (PTPN12) is considered to be a tumor suppressor. It plays a significant role in human cancer, but its clinicopathologic and prognostic significance in esophageal squamous cell carcinoma (ESCC) has not yet been elucidated. Using Western blot, we evaluated the PTPN12 expression in 20 pairs of surgically resected esophageal tissues. The PTPN12 was detected by immunochemistry in a tissue microarray from 260 surgically resected ESCCs, of which 260 were from primary cancer sites and 60 were from matched paracancerous normal tissues. Statistical analyses were applied to test the associations between PTPN12 expression, clinicopathologic factors, and prognosis. Western blots showed that the expression level of PTPN12 was higher in normal paracancerous esophageal tissues than in ESCC tissues. By immunohistochemical analysis, high and low expression of PTPN12 was found in 62.1% and 37.9% of ESCCs, respectively. After multivariate analysis, along with pN status and tumor grade, the protein expression level of PTPN12 was an independent and significant predictive factor (p<0.001). Patients with PTPN12-high tumors had a longer disease-free survival and overall survival (p=0.002 and p=0.001, respectively), especially for those with stage II disease (both p<0.001).
assistant
Our study suggests that PTPN12 protein expression is a valuable biomarker for ESCC patients. High expression of PTPN12 is associated with favorable disease-free survival and overall survival in ESCC patients. Final Decision: yes